2016
DOI: 10.1186/s12957-016-0965-7
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: BackgroundPrimary brain melanomas are very infrequent and metastasis outside central nervous system very uncommon. There are some cases in the literature about primary melanoma in the temporal lobe; nevertheless, the insular location has never been described.Case presentationThe patient presented as left insular intraparenchymal hematoma with multiple bleedings. Complementary tests did not show any tumoral nor vascular pattern in relation with these bleedings. A complete surgical resection was performed, and t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 25 publications
0
4
0
Order By: Relevance
“…Combination dabrafenib and trametinib has also been shown to be superior to dabrafenib monotherapy in a BRAFV600E mutant and CDKN2A deficient intracranial murine glioma model [24]. Clinical experience of combination BRAF and MEK inhibition in primary CNS tumors is reported in case reports in patients with meningioma, craniopharyngioma and primary brain melanoma [25][26][27]. Our two cases add to a recent case report of combination BRAF and MEK inhibitor use in anaplastic pleomorphic xanthoastrocytoma following prior progression with vemurafenib monotherapy in which the addition of an MEK inhibitor appears to overcome previous BRAF inhibitor resistance [28].…”
Section: Discussionmentioning
confidence: 99%
“…Combination dabrafenib and trametinib has also been shown to be superior to dabrafenib monotherapy in a BRAFV600E mutant and CDKN2A deficient intracranial murine glioma model [24]. Clinical experience of combination BRAF and MEK inhibition in primary CNS tumors is reported in case reports in patients with meningioma, craniopharyngioma and primary brain melanoma [25][26][27]. Our two cases add to a recent case report of combination BRAF and MEK inhibitor use in anaplastic pleomorphic xanthoastrocytoma following prior progression with vemurafenib monotherapy in which the addition of an MEK inhibitor appears to overcome previous BRAF inhibitor resistance [28].…”
Section: Discussionmentioning
confidence: 99%
“…Novel biologics and targeted therapies are promising and have a favorable side effect profile than cytotoxic chemotherapies. Targeted therapy agents like dabrafenib and vemurafenib can be effective adjuvant agents in patients with BRAF mutant melanomas [18]. Immune checkpoint inhibitor therapy with cytotoxic T lymphocyte antigen-4 inhibitor Ipilimumab and programmed death-1 inhibitors Nivolumab and Pembrolizumab has shown positive outcomes in patients with advanced melanomas [19].…”
Section: Discussionmentioning
confidence: 99%
“…The meningeal vessels of the left parietal lobe were thrombosed and around these vessels we observed many atypical pleomorphic cells with cytoplasmatic melanin pigment; the neoplasm had probably first developed from the leptomeningeal space around the brain stem, and after, spread to the subarachnoid space of the left parietal lobe. In fact, it should be borne in mind also that melanocytes far outnumber leptomeninges of the skull base and cervical cord [ 37 , 38 ] and the most common locations of primary cerebral melanoma are the anterolateral face of the spinal cord and the postero-lateral face of the brain stem [ 39 ]. In agreement with this author, primary cerebral melanoma was observed also in the posterior fossa in the cerebellopontine angle [ 40 , 41 ] and Arantes [ 42 ] reported 13 cases of primary malignant melanoma derived from the pineal body.…”
Section: Discussionmentioning
confidence: 99%